Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.53 |
| ▸ | FFAR4 | Q5NUL3 | 12/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19967184 | 0.81 | FFAR4 (0.52) | FFAR4FFAR1PTPN1 | |
| SCHEMBL19967144 | 0.76 | FFAR4 (0.60) | ESR1FFAR4FFAR1 | |
| SCHEMBL19967336 | 0.75 | TDP1 (0.52) | ESR1ESR2MEN1KMT2A | |
| SCHEMBL19967045 | 0.75 | FFAR4 (0.49) | ESR1FFAR4FFAR1MEN1KMT2A | |
| SCHEMBL12081307 | 0.73 | ESR1 (0.44) | ESR1ESR2 | |
| SCHEMBL19967065 | 0.73 | FFAR4 (0.50) | FFAR4FFAR1 | |
| SCHEMBL19967157 | 0.72 | FFAR4 (0.74) | FFAR4FFAR1 | |
| SCHEMBL19967187 | 0.70 | FFAR1 (0.53) | FFAR4FFAR1 | |
| SCHEMBL4144745 | 0.68 | FFAR4 (0.55) | FFAR4FFAR1PTPN1 | |
| SCHEMBL20246096 | 0.65 | FFAR4 (0.54) | FFAR4FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3509588-B1 | BICYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS | INTEGRAL HEALTH INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20210347768-A1 | BICYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS | VALO HEALTH, INC. | 2021-11-11 | — | — | US | disclosed |
| US-10865201-B2 | Bicyclic compounds useful as GPR120 modulators | VALO HEALTH, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| US-20190218208-A1 | BICYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS | VALO HEALTH, INC. | 2019-07-18 | — | — | US | disclosed |
| WO-2018049328-A1 | BICYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS | NUMERATE, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10865201-B2 | Bicyclic compounds useful as GPR120 modulators | GPR119, GPR180, GPR65 | ESR1 505/4885FFAR4 38/4885FFAR1 20/4885 |
| US-20190218208-A1 | BICYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS | GPR119, GPR180, GPR65 | ESR1 505/4885FFAR4 38/4885FFAR1 20/4885 |
| US-20210347768-A1 | BICYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS | GPR119, GPR180, GPR65 | ESR1 505/4885FFAR4 38/4885FFAR1 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.